We are live on ! Find out more

Exelixis

EXEL

Market cap $16.4B

66.28 USD

+0.93

1.42%

At close Updated Oct 28, 4:00 PM EDT

Pre-market

After hours

66.00

-0.28

0.42%

1 day

1.42%

5 days

2.38%

1 month

13.55%

3 months

17.29%

6 months

47.52%

Year to date

52.09%

1 year

65.37%

5 years

204.6%

10 years

509.19%

About: Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Employees: 1,077

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 51.1%

Neutral 42.6%

Negative 6.4%

Riverwater Partners Sustainable Value Strategy Q3 2026 Portfolio Update

The Sustainable Value Strategy trailed its benchmark, the Russell 2500 Value Index, in the third quarter. New positions include Lineage, Birkenstock, Matador Resources, KBR and ICON. InterDigital, Stevanato Group and Exelixis rounded out our top contributors.

Riverwater Partners Sustainable Value Strategy Q3 2026 Portfolio Update

Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock

Bristol Myers Squibb TodayBMYBristol Myers Squibb$61.20 -0.28 (-0.45%) As of 01:50 PM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$42.52▼$68.64Dividend Yield4.12%P/E Ratio13.48Price Target$65.50Add to WatchlistGLP-1 agonists may have taken up most of the attention when it comes to game-changing drugs in the last couple of years, but the oncology landscape is heating up as well, and investors may see a transformation for some long-standing firms in the space.

Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock

The Motley Fool

Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy

Regulators in the U.S. extended the review period for Exelixis' request to approve a new cancer drug. However, the company's most important medicine is performing well and still has several years of growth before facing generic competition.

Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy

Exelixis Rises with Earnings on Tap

Shares of oncology company Exelixis, Inc. (EXEL) are higher by 177% since 2017.

Exelixis Rises with Earnings on Tap

Zacks Investment Research

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks Investment Research

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2026 financial results will be released on Thursday, October 29, 2026, after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event will be available via the Internet from the company's website. To access the conference call, please register using this link.

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

Zacks Investment Research

Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. ( NASDAQ : EXEL) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm

Zacks Investment Research

Here's Why Exelixis (EXEL) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Exelixis (EXEL) is a Strong Value Stock

See News Rankings

Price charts implemented using Lightweight Charts™